



## Resolution n°9-2024-e

### Cost Extension for the Project “Global long-acting drug combination development” (GLAD)

Recalling Unitaid Board Resolution R2-2020-e, which authorized the Executive Director to commit up to US\$ 6,962,027 for the project entitled, “Global long-acting drug combination development” (GLAD) (the “Project”) to be implemented by University of Washington for a 4-year period;

Noting that in 2023, the Secretariat approved a no-cost extension to the duration of funding for the Project of 5 months, ending on 31 May 2024;

Taking into account the assessment by the PRC and the Secretariat’s recommendations, the Board authorizes the Executive Director, subject to the availability of funds, to commit additional funding of up to US\$ 2,634,208 for the Project and to extend the duration of funding for the Project by a further 15 months up to 31 August 2025.

The additional funding and extension to the Project duration are conditional upon signature of an amendment to the legal agreement between Unitaid and the University of Washington.

A handwritten signature in blue ink that reads "Marisol Touraine". Below the signature is a horizontal line.

Marisol Touraine  
Chair of the Executive Board

Date: 29 January 2024